Ochsner Cancer Institute Offers New Hope Through Early Phase Trials

The Precision Cancer Therapies Program at Ochsner Cancer Institute offers new hope to cancer patients who may have thought they had no options. Fewer than 3% of adult cancer patients in Louisiana enroll in clinical trials; yet enrolled patients typically experience better outcomes than those who do not participate.

Through the program, patients are given access to early phase clinical trials that allow them to receive innovative therapies years before they are available. This connects Ochsner’s clinical expertise with the world-renowned Translational Genomics Research Institute – or TGEN.

For more information on clinical trials, visit or call 504-800-6370.

– Dr. Marc Matrana, Medical Director, Ochsner Precision Cancer Therapies Program